Core Technology

CancerFree
2 min readJun 7, 2022

Compared to other technologies currently available in the market, the exclusive technology of CancerFree Biotech is to isolate a very small number of circulating tumor cells that enter the bloodstream from in-situ tumors and increase the total number of circulating tumor cells through our exclusive cell culture technology.

◎ Ex Vivo Avatar (E.V.A.)

The first commercializable CDO culture system
We develop a Circulating Tumor Cell-Derived Organoid (CDO) culture system containing 3D scaffolds to facilitate tumor cell proliferation:

- 3D structure mimics in vivo extracellular matrix.
- Replicate in vivo environment for tumorigenesis.
- High efficacy: successful rate about 90%. (in 100+ cancer types).
- High efficiency: 1,000~100,000 folds proliferation within 4 weeks.
- Over 900 sucessful cases.
- 100 types of generic drugs can be tested.

Compare with other labs
Immunofluorescence staining for CTC-derived organoid (CDO)

◎ Publications

Ex Vivo Expanded Circulating Tumor Cells for Clinical Anti-Cancer Drug Prediction in Patients with Head and Neck Cancer

Ex Vivo Expansion and Drug Sensitivity Profiling of Circulating Tumor Cells from Patients with Small Cell Lung Cancer

Circulating tumor cells (CTC)-derived organoids for clinical anticancer drug prediction

Patient-Derived Tumor Chemosensitization of GKB202, an Antrodia Cinnamomea Mycelium-Derived Bioactive Compound

Correlation between drug sensitivity profiles ofcirculating tumour cell-derived organoids and clinicaltreatment response in patients with pancreatic ductaladenocarcinoma

--

--